No Data
Hong Kong stocks movement | Kangnuo Ya-B (02162) rises over 7% as BCMA/CD3 dual antibody goes overseas through NewCo with funds exceeding 0.6 billion USD.
Convoy Global Holdings Limited (02162) rose over 7%, as of the time of writing, it increased by 7.05%, trading at HKD 41, with a transaction volume of HKD 19.9362 million.
Conoya-B (2162.HK): Achieved new success overseas, with CM336's self-reinforcing layout accelerating.
On November 17, the company announced that its BCMA/CD3 dual-acting antibody CM336 has been externally licensed in the form of NewCo, with Platina, a subsidiary of Ouro Medicines, as the counterpart.
Kangnuo Ya-B (02162): Entered into an exclusive licensing agreement for CM336 with Platina Medicines Ltd.
Kangnaoya-B (02162) announced on November 17, 2024 that Kangnaoya biomedical technology (achieved...
Kangnoah-B (2162.HK) Announcement Review: Siptuzumab vedotin approved for listing, promising commercial prospects.
Event: The China National Medical Products Administration (NMPA) has recently approved the new drug market application for Sipuqiba monoclonal antibody (Anti-IL-4Rα monoclonal antibody; trade name: Kangyueda; research and development code: CM310), indicated for adults.
Guangzhou Municipal Party Committee Financial Office: Promote biomedical enterprises to go public.
Guangzhou Municipal Party Committee Deputy Director of the Financial Office, Wen Keyin, stated at a press conference that next steps will continue to create a favorable environment for venture capital development, nurture and strengthen patient capital, guide venture capital institutions to accurately meet the financing needs of biomedical enterprises; focus on the growth characteristics and financing needs of biomedical enterprises, carry out efficient incubation, production-financing matching, and listing cultivation work; continue to promote the integration of insurance institutions in Guangzhou with the characteristics of the biomedical industry, increase research and development efforts for medical instruments, biomedical products, etc. Specific measures include guiding venture capital and venture capital to support the long-term development of the biomedical industry, and increasing support for biomedical
The tenth batch of national pharmaceutical collection and procurement volume reporting work in mainland China has been initiated, involving 62 varieties, with injections accounting for over half.
According to internal media reports, with the recent conclusion of the tenth batch of national organized pharmaceutical joint procurement conference, the work of reporting the tenth batch of national pharmaceutical joint procurement officially started today (18th). Shanxi Province Pharmaceutical Centralized Competitive Bidding Procurement Network issued the "Notice on Submitting the Demand Quantity of the Tenth Batch of National Organized Pharmaceutical Centralized Procurement Varieties" on Wednesday (16th), with the deadline for medical institutions to report from October 18th to 28th, using an online direct reporting method. When the reported quantity of medical institutions is less than 80% of their historical procurement volume, an explanation is required. For medical institutions with historical procurement volumes that do not participate in reporting quantities, monitoring will be enforced in the later stage.
No Data
No Data